ZOM - Mainly based on Fundamental Analysis
Zomedica Pharmaceuticals (NYSEMKT:ZOM) has priced a public offering of ~133.3M common shares, together with warrants to purchase up to same number of common shares, at a combined price of 0.15/share and accompanying warrant, for expected gross proceeds of ~20M.
Two-year warrants have an exercise price of 0.15/share.
Net proceeds will be used for the development of TRUFORMA diagnostic platform, including making milestone payments, working capital and other general corporate purposes.
Closing date is May 29
Two-year warrants have an exercise price of 0.15/share.
Net proceeds will be used for the development of TRUFORMA diagnostic platform, including making milestone payments, working capital and other general corporate purposes.
Closing date is May 29
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.